Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence
Year: 2024
Type: article
Abstract: BACKGROUND: The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes. METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS AND CONCLUSION: Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics.
Source: Hepatology Communications
Authors: Arun J. Sanyal, Kris V. Kowdley, Nancy S. Reau, Nikolaos T. Pyrsopoulos, Christopher Allen, Zeev Heimanson, Jasmohan S. Bajaj
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W4396796406